Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

e surgery or radiation therapy, and some of these patients are cured. For many others, though, the disease recurs. At this point, the recurrent disease is treated with hormone therapy, and most patients initially respond well to this treatment. Eventually, however, the tumor cells become resistant to the hormones -- or "hormone-refractory" -- and the tumor again progresses. Increasingly, chemotherapy is being used as an effective first-line treatment for hormone-refractory prostate cancer. However, it is not a cure, and so this is creating a need for effective therapeutic options for these patients once they have progressed.

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum family of compounds. Over the past two decades, platinum-based drugs have become a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. Unlike the platinum drugs currently on the market, all of which require intravenous administration, satraplatin is an orally bioavailable compound and is given as capsules that patients can take at home.

GPC Biotech and Pharmion have a co-development and license agreement under which Pharmion has been granted exclusive commercialization rights to satraplatin for Europe and certain other territories. GPC Biotech in-licensed satraplatin from Spectrum Pharmaceuticals, Inc. in 2002.

Satraplatin has been studied in clinical trials involving a range of tumors. Trials evaluating the effects of satraplatin in combination with radiation therapy, in combination with other cancer therapies and in a number of cancer types are underway or planned.

About Pharmion

Pharmion is a biopharmaceutical company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical ... company engaged primarily in the development of brachytherapy ... applications, today announced that it has filed a ... and Drug Administration ("FDA") for marketing clearance for ... 513(f)(2) of the U.S. Food, Drug and Cosmetic ...
(Date:12/24/2014)... 23, 2014   Assurex Health, a personalized ... healthcare providers for behavioral health and chronic pain ... million in equity financing from new and existing ... President and Chief Executive Officer. The ... of Assurex Health,s GeneSight ®  products.  ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 2011 Savvy executives in pharmaceutical commercial functions ... in today,s volatile healthcare environment. Quantitative and qualitative ... for increased resources, justify costs, or signal necessary ... presidents, directors, and managers tasked with right-sizing investment ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the ... European Medicines Agency (EMA) has granted orphan designation for ... B. Orphan designation in the European Union provides several ... launch and access to the central authorization procedure. ...
Cached Medicine Technology:Pharmaceutical Investment & Cost Benchmarks Accessed Quickly Through Best Practices, LLC's New Database Search Function 2Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... , , California emergency ... , SAN FRANCISCO, June 29 CalRHIO announced today that ... of Southern California to measure savings resulting from physicians ... statewide Health Information Exchange (HIE). The first phase of the ...
... Carolinas HealthCare System has organized a ... cardiovascular services in North and South Carolina. , ... Institute (SHVI) represents a combination of Sanger Clinic, ... Institute will continue serving as a regional referral center for ...
... Scratches Surface in Terms of Meeting Seniors, Realistic Needs , ... the 2009 session of the Texas Legislature prior to the ... the Texas Health Care Association (THCA) said that while thankful ... for Medicaid-financed nursing home care, substantially more investment is required ...
... behaviors at bay , MONDAY, June 29 (HealthDay News) -- ... these days some aggressors apparently operate electronically. , A ... 10 have either bullied classmates or been bullied by them, ... the National Institutes of Health, released online June 29 in ...
... ... (VIDA) working in collaboration with colleagues at Vector Tobacco, Inc. and Duke University Medical School ... kicking the tobacco habit. , ... Manhasset, NY (Vocus) June 29, 2009 -- Scientists at the National Institute on ...
... , , , JACKSONVILLE, Fla., ... published online in Diabetologia by the European Association for ... use of insulin glargine (Lantus, sanofi-aventis) and the development ... editorial, cautioned against over-interpretation of their limited data and ...
Cached Medicine News:Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 2Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 3Health News:Sanger Clinic Lends Its Name to New Heart Care Institute Serving NC and SC 2Health News:THCA on 2009 Legislative Session: Seniors' Medicaid-Financed Nursing Home Care Requires Substantially More Investment as Population Ages, Care Needs Grow 2Health News:Cyber Bullying Affects One in 10 Students 2Health News:Cyber Bullying Affects One in 10 Students 3Health News:News from the Latest Issue of Molecular Medicine Kicking The Habit - It's In The Genes 2Health News:AACE Response to Insulin Glargine Cancer Risk Articles in Diabetologia 2
For the quantitative in vitro determination of Digoxin in human serum....
For the quantitative in vitro determination of Microalbumin in urine....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: